{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T02:06:03Z","timestamp":1775873163931,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002807","name":"Carla Boetes Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002807","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.clbc.2013.12.015","type":"journal-article","created":{"date-parts":[[2014,1,4]],"date-time":"2014-01-04T02:16:34Z","timestamp":1388801794000},"page":"315-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["A Model to Predict Pathologic Complete Response of Axillary Lymph Nodes to Neoadjuvant Chemo(Immuno)Therapy in Patients With Clinically Node-Positive Breast Cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"Robert-Jan","family":"Schipper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Moossdorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patty J.","family":"Nelemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grard A.P.","family":"Nieuwenhuijzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc J.A.","family":"Strobbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudi M.H.","family":"Roumen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franchette","family":"van den Berkmortel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivianne C.G.","family":"Tjan-Heijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina G.H.","family":"Beets-Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc B.I.","family":"Lobbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein L.","family":"Smidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2013.12.015_bib1","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1245\/s10434-012-2484-2","article-title":"The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer","volume":"19","author":"Alvarado","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2013.12.015_bib2","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1245\/s10434-013-2902-0","article-title":"Early assessment of axillary response with 18F-FDG PET\/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla","volume":"20","author":"Koolen","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2013.12.015_bib3","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1200\/JCO.2002.20.5.1304","article-title":"Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes","volume":"20","author":"Rouzier","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2013.12.015_bib4","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ejca.2009.04.029","article-title":"Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer","volume":"45","author":"Straver","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2013.12.015_bib5","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2013.12.015_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jso.21535","article-title":"Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection","volume":"102","author":"Ashikaga","year":"2010","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.clbc.2013.12.015_bib7","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.ejca.2009.02.012","article-title":"Late morbidity associated with a tumour-negative sentinel lymph node biopsy in primary breast cancer patients: a systematic review","volume":"45","author":"Liu","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2013.12.015_bib8","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1245\/s10434-007-9759-z","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically\u00a0negative axillary nodal status at presentation","volume":"15","author":"Gimbergues","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2013.12.015_bib9","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1002\/cncr.26102","article-title":"Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy","volume":"117","author":"Pecha","year":"2011","journal-title":"Cancer"},{"issue":"24 suppl","key":"10.1016\/j.clbc.2013.12.015_bib10","article-title":"The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy\u2014results from the ACOSOG Z1071 trial","volume":"72","author":"Boughey","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2013.12.015_bib11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2013.12.015_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/ejso.2002.1385","article-title":"Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy","volume":"29","author":"Schijven","year":"2003","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clbc.2013.12.015_bib13","unstructured":"Nationaal Borstkanker Overleg Nederland (NABON). Guideline Breast Carcinoma, 2004. Amsterdam, The Netherlands,\u00a02004."},{"key":"10.1016\/j.clbc.2013.12.015_bib14","unstructured":"Nationaal Borstkanker Overleg Nederland (NABON). Guideline Breast Carcinoma, 2008. Amsterdam, The Netherlands.\u00a02008."},{"key":"10.1016\/j.clbc.2013.12.015_bib15","unstructured":"Nationaal Borstkanker Overleg Nederland (NABON). Guideline Breast Carcinoma, 2012. Amsterdam, The Netherlands,\u00a02012."},{"key":"10.1016\/j.clbc.2013.12.015_bib16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0140-6736(11)61823-0","article-title":"The 2011 EBCTCG polychemotherapy overview","volume":"379","author":"Palmieri","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2013.12.015_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00000478-200301000-00002","article-title":"Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma","volume":"27","author":"Harris","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clbc.2013.12.015_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2559.2011.03916.x","article-title":"Histological grade of invasive carcinoma of the breast assessed on needle core biopsy\u2014modifications to mitotic count assessment to improve agreement with surgical specimens","volume":"59","author":"O'Shea","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.clbc.2013.12.015_bib19","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1200\/JCO.2006.08.2271","article-title":"Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome","volume":"25","author":"Mazouni","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2013.12.015_bib20","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S1470-2045(11)70378-3","article-title":"A\u00a0common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints","volume":"13","author":"Fumagalli","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2013.12.015_bib21","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1245\/s10434-009-0612-4","article-title":"Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases","volume":"16","author":"Sakakibara","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2013.12.015_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/aos\/1176344552","article-title":"Bootstrap methods: another look at the jackknife","volume":"7","author":"Efron","year":"1979","journal-title":"Ann Statist"},{"key":"10.1016\/j.clbc.2013.12.015_bib23","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0895-4356(01)00341-9","article-title":"Internal validation of predictive models: efficiency of some procedures for logistic regression analysis","volume":"54","author":"Steyerberg","year":"2001","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clbc.2013.12.015_bib24","series-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis","author":"Harrell","year":"2001"},{"key":"10.1016\/j.clbc.2013.12.015_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.clbc.2013.12.015_bib26","first-page":"411","article-title":"What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models","volume":"66","author":"Babyak","year":"2004","journal-title":"Psychosom Med"},{"key":"10.1016\/j.clbc.2013.12.015_bib27","first-page":"154","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"41","author":"Elston","year":"2002","journal-title":"Histopathology"},{"key":"10.1016\/j.clbc.2013.12.015_bib28","doi-asserted-by":"crossref","first-page":"e37379","DOI":"10.1371\/journal.pone.0037379","article-title":"How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists","volume":"7","author":"Varga","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2013.12.015_bib29","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/j.1742-1241.2005.00546.x","article-title":"Biological characteristics of breast cancer at the primary tumour and the involved lymph nodes","volume":"59","author":"Dikicioglu","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clbc.2013.12.015_bib30","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.3109\/02841860902988688","article-title":"The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer","volume":"48","author":"Sjostrom-Mattson","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clbc.2013.12.015_bib31","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/bjs.7073","article-title":"Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer","volume":"97","author":"Straver","year":"2010","journal-title":"Br J Surg"},{"key":"10.1016\/j.clbc.2013.12.015_bib32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/SLA.0b013e31820b01f1","article-title":"Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer","volume":"253","author":"Lambregts","year":"2011","journal-title":"Ann Surg"},{"key":"10.1016\/j.clbc.2013.12.015_bib33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/RLI.0b013e318277f056","article-title":"Noninvasive nodal staging in patients with breast cancer using gadofosveset-enhanced magnetic resonance imaging: a feasibility study","volume":"48","author":"Schipper","year":"2013","journal-title":"Invest Radiol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820913003200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820913003200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:13:10Z","timestamp":1761513190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820913003200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1526820913003200"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2013.12.015","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Model to Predict Pathologic Complete Response of Axillary Lymph Nodes to Neoadjuvant Chemo(Immuno)Therapy in Patients With Clinically Node-Positive Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2013.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}